NTRK1 and neoplasm: We have shown that reducing MAPK activity by sorafenib, a multikinase inhibitor that targets RAF and several upstream receptor tyrosine kinases, in our UBC-NRASG12V mice had no effect on immune surveillance but inhibited the formation of granuloma-like immune clusters, while its long-term impact on tumor development remains to be determined (Chan et al. 2024).